TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines

Haematologica

Volumn 92, Issue 6, 2007, Pages 803-811

  Moreaux, Jérôme ^a,c   Hose, Dirk ^d   Jourdan, Michel ^a,c   Reme, Thierry ^c   Hundemer, Michael ^d   Moos, Marion ^d   Robert, Nicolas ^a   Moine, Philippe ^a   De Vos, John ^a,b,c   Goldschmidt, Hartmut ^d   Klein, Bernard ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

c maf; Gene expression profiles; Myeloma; TACI

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BETA7 INTEGRIN; CYCLIN D2; HYBRID PROTEIN; PROTEIN TACI; RECEPTOR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR C MAF; UNCLASSIFIED DRUG; BETA INTEGRIN; CCND2 PROTEIN, HUMAN; CYCLINE; MAF PROTEIN, HUMAN; TNFRSF13B PROTEIN, HUMAN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; CELL MATURATION; CONTROLLED STUDY; EXPRESSED SEQUENCE TAG; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; UPREGULATION; BONE MARROW; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

BONE MARROW; CYCLINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN BETA CHAINS; MULTIPLE MYELOMA; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-MAF; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN;

EID: 34347216736     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10574     Document Type: Article

References (42)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;10:607-18.
2. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8.
3. Dirk Hose J-FR, Ittrich C, De Vos J, Rème T, Benner A, Mahtouk K, et al. Molecular classification of multiple myeloma (MM) based on gene expression profiling (GEP) and fluorescence in situ hybridisation (FISH) is an independent predictor for event free survival (EFS). Blood 2005; 106:507.
4. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
5. Zhang XG, Bataille R, Widjenes J, Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992;69:1373-6.
6. Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-α is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998;161:2692-9.
7. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000;111:626-34.
8. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003;17:764-74.
9. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002;99:1405-10.
10. Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, Moreaux J, et al. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 2006;25:7180-91.
11. Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005; 24:3512-24.
12. Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004;103:1829-37.
13. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999;10:65-70.
14. De Vos DH J, Rème T, Tarte, Jérôme Moreaux, Karéne Mahtouk, Michel Jourdan, Hartmut Goldschmidt, Jean-François Rossi, Friedrich W. Cremer, Bernard Klein. Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 2006;210:86.
15. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2003;104:689-94.
16. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-57.
17. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75.
18. Do RK, Hatada E, Lee H, Tourigny MR, Hubert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-64.
19. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687-95.
20. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 1999;13:382-7.
21. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-66.
22. Hsu BL, Harless SM, Lindsley RC, Hubert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002;168:5993-6.
23. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: A Tutorial on B Cell Survival. Annu Rev Immunol 2003;21:231-64.
24. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006;66:6675-82.
25. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005;106:1021-30.
26. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994;83:3654-63.
27. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 1998;91:4727-37.
28. Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF, et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 1999;163:514-24.
29. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000;14:188-97.
30. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002;100:1113-22.
31. Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 2003;4:210.
32. De Vos J, Hose D, Reme T, Tarte K, Moreaux J, Mahtouk K, et al. Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 2006;210:86-104.
33. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005; 36: 1113-9.
34. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J, Jr. Gene expression profiting of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003;102:592-600.
35. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005; 105:4845-8.
36. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-9.
37. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κ B. Blood 1996; 87:1104-12.
38. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006;66:812-9.
39. Bergsagel PL CJ, Chesi M, VanWier S, Keats JJ, Sebag M, Chng W, et al. Promiscuous Mutations Frequently Activate the non-canonical NFkB pathway in multiple myeloma (MM). Blood 2006;108(11).
40. Sii-Felice K, Pouponnot C, Gillet S, Lecoin L, Girault JA, Eychene A, et al. MafA transcription factor is phosphorylated by p38 MAP kinase. FEBS Lett 2005;579:3547-54.
41. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-α and insulin-like growth factor 1. Cell Death Differ 2000;7:1244-52.
42. Rossi JF, Borghini-FI, Moreaux J, Requirand G, Bouseida S, Picard M, et al. A Phase I/II Study of TACI-Ig to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma or active previously-treated Waldenström's macroglobulinemia. Blood 2005;106:Poster Session 770-II[Abstract].